20:01 , Nov 16, 2017 |  BC Innovations  |  Tools & Techniques

Yeast against aggregation

In drug discovery for neurodegenerative diseases, the emphasis is on finding better models of neuronal systems that recapitulate synapses, neuroinflammation and the pathological accumulation of toxic aggregates. Yumanity Therapeutics LLC and a handful of academic...
18:17 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic; endocrine / metabolic

INDICATION: Non-alcoholic steatohepatitis (NASH); metabolic syndrome Patient sample, mouse and non-human primate (NHP) studies suggest that enhancing TMBIM1 expression could help treat non-alcoholic steatohepatitis (NASH) and metabolic syndrome. In liver tissue samples, levels of TMBIM1 mRNA...
07:00 , Apr 25, 2016 |  BioCentury  |  Emerging Company Profile

Yeast on the brain

Yumanity Therapeutics LLC is using an iterative loop of phenotypic screens to tackle diseases caused by misfolded proteins. The company, led by veteran biotech executive Tony Coles and backed by investors with long-term horizons, is...
08:00 , Feb 15, 2016 |  BioCentury  |  Finance

Breaking from tradition

Traditional VCs are missing from the new series A syndicate backing Yumanity Therapeutics LLC, and the biotech says that was its plan. The neurodegeneration company wanted investors with exceedingly long time horizons and the ability...
08:00 , Dec 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Various E3 ubiquitin ligase; SMAD specific E3 ubiquitin protein ligase 2 (SMURF2); NEDD4 family E3 ubiquitin-protein ligase (RSP5)...
08:00 , Dec 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) a-Synuclein (SNCA); NEDD4 family E3 ubiquitin protein ligase (RSP5); neural precursor cell expressed developmentally downregulated...
07:00 , Aug 30, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); amyotrophic lateral sclerosis (ALS); Parkinson's disease (PD); Huntington's disease (HD) Neural precursor cell expressed developmentally...